WO2005094497A3 - Administration systemique d'agents therapeutiques au systeme nerveux central - Google Patents

Administration systemique d'agents therapeutiques au systeme nerveux central Download PDF

Info

Publication number
WO2005094497A3
WO2005094497A3 PCT/US2005/009714 US2005009714W WO2005094497A3 WO 2005094497 A3 WO2005094497 A3 WO 2005094497A3 US 2005009714 W US2005009714 W US 2005009714W WO 2005094497 A3 WO2005094497 A3 WO 2005094497A3
Authority
WO
WIPO (PCT)
Prior art keywords
nervous system
central nervous
therapeutic moiety
therapeutics
blood
Prior art date
Application number
PCT/US2005/009714
Other languages
English (en)
Other versions
WO2005094497A2 (fr
Inventor
Shawn Hochman
Original Assignee
Univ Emory
Shawn Hochman
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Emory, Shawn Hochman filed Critical Univ Emory
Publication of WO2005094497A2 publication Critical patent/WO2005094497A2/fr
Publication of WO2005094497A3 publication Critical patent/WO2005094497A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
    • A61K49/0056—Peptides, proteins, polyamino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/6415—Toxins or lectins, e.g. clostridial toxins or Pseudomonas exotoxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
    • A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
    • A61K49/0041—Xanthene dyes, used in vivo, e.g. administered to a mice, e.g. rhodamines, rose Bengal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
    • A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
    • A61K49/0041—Xanthene dyes, used in vivo, e.g. administered to a mice, e.g. rhodamines, rose Bengal
    • A61K49/0043—Fluorescein, used in vivo
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
    • A61K49/0045—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent agent being a peptide or protein used for imaging or diagnosis in vivo
    • A61K49/0047—Green fluorescent protein [GFP]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Toxicology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pathology (AREA)
  • Radiology & Medical Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

La présente invention a trait à des procédés de traitement de troubles nerveux comprenant l'administration dans le système circulatoire d'un patient nécessitant un tel traitement, d'une molécule de fusion neuroactive comportant un groupe fonctionnel thérapeutique et un groupe fonctionnel apte au transport trans-synaptique du groupe fonctionnel thérapeutique vers un neurone sélectionné à travers la barrière hémato-encéphalique ou la barrière hémato-nerveuse. Des protéines thérapeutiques de grande dimension peuvent être transportées par les procédés de l'invention. Le groupe fonctionnel thérapeutique peut être ciblée vers des neurones dans le système nerveux central ainsi que dans le système nerveux périphérique, par exemple, vers des nerfs impliqués dans la sensation tels que des nerfs des systèmes de la douleur, le système nerveux entérique, le système nerveux autonome, et autres. Des dispositifs classiques tels que des comprimés, des moyens d'injection intraveineuse, des suppositoires, et d'autres moyens connus de l'art pour l'administration dans le système circulatoire peuvent être utilisés.
PCT/US2005/009714 2004-03-24 2005-03-24 Administration systemique d'agents therapeutiques au systeme nerveux central WO2005094497A2 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US55610904P 2004-03-24 2004-03-24
US60/556,109 2004-03-24
US63909104P 2004-12-23 2004-12-23
US60/639,091 2004-12-23

Publications (2)

Publication Number Publication Date
WO2005094497A2 WO2005094497A2 (fr) 2005-10-13
WO2005094497A3 true WO2005094497A3 (fr) 2006-05-18

Family

ID=35064394

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2005/009714 WO2005094497A2 (fr) 2004-03-24 2005-03-24 Administration systemique d'agents therapeutiques au systeme nerveux central

Country Status (1)

Country Link
WO (1) WO2005094497A2 (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006070290A2 (fr) * 2004-06-23 2006-07-06 Ferguson Ian A Agents et procedes pour le diagnostic et le suivi precoces de la maladie d'alzheimer et d'autres troubles neurologiques
US20110077204A1 (en) * 2006-01-24 2011-03-31 Kagoshima University Agent for Targeted Drug Delivery To Cerebral Neurons
CA2656104A1 (fr) * 2006-06-30 2008-01-10 Board Of Regents, The University Of Texas System Procedes et agents d'imagerie bases sur le fragment c de la toxine tetanique, traitements d'ensembles de donnees pour la microscopie confocale
CN114163535A (zh) * 2021-11-09 2022-03-11 湖北科技学院 一种以ttc作为神经元细胞靶向基因的融合蛋白的诱导表达
WO2024026306A1 (fr) * 2022-07-25 2024-02-01 Wisconsin Alumni Research Foundation Conjugués ciblant la barrière hémato-nerveuse et procédés d'utilisation

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5684133A (en) * 1988-11-04 1997-11-04 Erziehungsdirektion Of The Canton Zurich Neurite growth regulatory factors, antibodies thereto, and pharmaceutical compositions
US20030083299A1 (en) * 2000-11-04 2003-05-01 Ferguson Ian A. Non-invasive delivery of polypeptides through the blood-brain barrier

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5684133A (en) * 1988-11-04 1997-11-04 Erziehungsdirektion Of The Canton Zurich Neurite growth regulatory factors, antibodies thereto, and pharmaceutical compositions
US20030083299A1 (en) * 2000-11-04 2003-05-01 Ferguson Ian A. Non-invasive delivery of polypeptides through the blood-brain barrier

Also Published As

Publication number Publication date
WO2005094497A2 (fr) 2005-10-13

Similar Documents

Publication Publication Date Title
IL267381A (en) A pharmaceutical preparation containing dextromethorphan and quinidine for the treatment of nervous disorders
WO2008039898A3 (fr) Procédés de traitement d'une blessure traumatique du système nerveux central
MX2020008274A (es) Metodos y composiciones para la administracion de proteinas terapeuticas.
WO2008054544A3 (fr) Procédé d'administration à travers la barrière hématoencéphalique
WO2006102596A3 (fr) Procede pour le traitement d'une lesion traumatique du systeme nerveux central
MX2009013574A (es) Formas de dosificacion solidas o semisolidas de liberacion modificada.
MX2009005339A (es) Suspensiones analgesicas de liberacion modificada.
CY1110391T1 (el) Αρυλβινυλαζακυκλοαλκανια και μεθοδοι παρασκευης και χρησεως τους
ATE411813T1 (de) Behandlungen mit botulinum toxin von neurologische und neuropsychiatrische krankheiten
WO2005027839A3 (fr) Procedes et reactifs pour le traitement des troubles immuno-inflammatoires
WO2001052878A3 (fr) Utilisation de copolymere 1 et de peptides et polypeptides connexes et cellules t traitees a l'aide de ces produits en therapie neuroprotective
WO2004105702A3 (fr) Compositions pharmaceutiques expansibles et procedes de traitement d'un trouble donne
WO2008036682A3 (fr) Traitement des troubles hépatiques par l'administration de conjugués de protéine associée au récepteur (rap)
CY1121822T1 (el) Βραδεια ενδοκοιλιακη χορηγηση
WO2001093893A3 (fr) Utilisation du copolymere 1 et des peptides et polypeptides associes, et lymphocytes t traites par ces derniers pour une therapie neuroprotectrice
WO2003092617A3 (fr) Combinaisons destinees au traitement de troubles cutanes inflammatoires
WO2007087154A3 (fr) Méthodes destinées à renforcer les effets thérapeutiques d'une neurotoxine
WO2005094497A3 (fr) Administration systemique d'agents therapeutiques au systeme nerveux central
WO2007095389A3 (fr) traitement de maladies hyperprolifEratives avec la camptothecine n-oxyde et des analogues de celle-ci
WO2008045378A3 (fr) Traitement d'hyperbilirubinémie infantile en utilisant des faibles dosages de stannsoporfine
WO2006138316A3 (fr) Methodes permettant d'administrer des molecules au systeme nerveux central
MY142346A (en) Medicament and method for reducing alcohol and/or tobacco consumption

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Country of ref document: DE

122 Ep: pct application non-entry in european phase